Physician profile
Ryan Geist
NPI 1659020022
$7,567.99
in general payments reported to CMS, 2019-2025
19 companies · $2,943 in 2025
The $2,943 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $182 · 2024: $4,443 · 2025: $2,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,175 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,175.01 |
| Education | $392.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,399.76 | 2024-2025 | |
| Janssen Biotech, INC. | $919.51 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $912.65 | 2023-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $912.57 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $622.37 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $563.92 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $478.07 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $348.28 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $346.24 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $269.02 | 2025 | |
| Blueprint Medicines Corporation | $191.47 | 2025 | Ayvakit |
| Genzyme Corporation | $148.80 | 2024-2025 | |
| Convatec INC. | $137.19 | 2024 | |
| Galderma Laboratories, L.P. | $109.68 | 2024 | |
| Incyte Corporation | $80.68 | 2024-2025 | Opzelura |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $41.86 | 2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.05 | 2025 | Cabtreo, Jublia |
| Organogenesis INC. | $32.14 | 2025 | Puraply Wound Matrix |
| Verrica Pharmaceuticals INC. | $16.73 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Geist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.